|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Avexa, of Melbourne, Australia, has been awarded a A$4.3 million (US$3.5 million) Australian government grant to develop a new generation of HIV antiviral drugs using fragment based drug design, a nontraditional research methodology. Avexa will work with the government's molecular and health technologies division to discover inhibitors of the HIV integrase enzyme, which conventional techniques are unable to identify. The program also can be applied to other antiviral targets. The grant program provides funding for up to half of eligible project expenditures for early-stage R&D. It also will help fund discovery and preclinical development required to advance candidates ...
Related newspaper, magazine, and journal articles:
|
|
Article: Research from Astellas Pharma, Inc. provide new ...
Biotech Week;
September 10, 2008 ;
700+ words
... ... see also Life Sciences). "Results ... colleagues, Astellas Pharma, Inc. The ... Fujita, Astellas Pharma Inc., Drug ... Azusawa, Life Sciences, Pharmacology ... Pharmaceuticals, Astellas Pharma Inc., Pharmaceutical ...
|
|